How many investments has Third Rock Ventures made?

Third Rock Ventures has 12 tracked investments, 3 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.

What stage does Third Rock Ventures invest at?

Third Rock Ventures invests at the Seed, Series A, Series B, Series C stages.

What is Third Rock Ventures's typical check size?

Third Rock Ventures typically writes checks of $100K – $5M.

What sectors does Third Rock Ventures focus on?

Third Rock Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Third Rock Ventures located?

Third Rock Ventures is headquartered in Boston, US.

Does Third Rock Ventures lead rounds?

Third Rock Ventures typically participates in rounds rather than leading them.

Who does Third Rock Ventures co-invest with?

Third Rock Ventures most often shares deals with Nextech Invest, Foresite Capital, Samsara BioCapital, among 13 tracked co-investors.

Third Rock Ventures

Venture capitalActively deploying

Boston · Seed–Series C · 60 people tracked

Also known as THIRD ROCK VENTURES, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Third Rock Ventures focuses on creating and building transformative healthcare and life sciences companies. It works closely with founders to discover, launch, build, and scale ventures developing breakthrough therapeutics and medical technologies across areas such as oncology, immunology, genetic medicine, gene therapy, precision genome engineering, and mental health. The firm emphasizes founding companies around ambitious scientific ideas that can address serious unmet medical needs and deliver meaningful patient impact, with a track record of advancing assets to FDA approval and successful acquisitions by major pharmaceutical companies.

Invests inBiotech Digital Health Healthtech Medical Devices Boston United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Series C

Check

$100K – $5M

Boston, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

2007

Last 12 months

8 investments

AUM

$3.8B

VC funds

Tracked investments

Team · 60 people

from the firm's website & public directories

Abbie Celniker· Partner· Massachusettsin

A biotech executive with over 30 years in senior R&D and leadership roles, she joined Third Rock Ventures in 2016, where she focuses on the formation, development, and strategy of portfolio companies. She previously served as CEO of Eleven Biotherapeutics and Taligen Therapeutics, and held senior roles at Novartis, Millennium Pharmaceuticals, and Wyeth.

a•••@thirdrockventures.comreveal

Andrea van Elsas· Partner· Oakland, Californiain

Andrea van Elsas joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He was previously CSO at Aduro Biotech, co-founded BioNovion, held immuno-oncology roles at Organon, and is a co-inventor on the original anti-CTLA-4 patents behind ipilimumab.

a•••@thirdrockventures.comreveal

Charles Homcy· Partner· San Francisco, California

A physician with extensive experience building and leading biotech companies, focused on forming companies developing novel therapeutics. He has been a clinical professor at UCSF Medical School and an attending physician at the San Francisco VA Medical Center since 1997, and previously co-founded Portola Pharmaceuticals, serving as its president and CEO.

Craig Muir· Partner· Massachusettsin

Craig Muir led the identification and integration of drug discovery and development technology platforms across Third Rock's portfolio, built platform systems for R&D and informatics, and contributed to scientific diligence. He helped expand the firm's San Francisco presence. He joined in 2007 and holds a B.S. in Physiology and Chemistry from UC Davis.

David Kaufman· Partner· Boston, Massachusettsin

Physician-scientist who joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He previously served as Chief Medical Officer and Head of Translational Development at the Gates Medical Research Institute and led Translational Oncology at Merck Research Laboratories.

d•••@thirdrockventures.comreveal

Jeffrey Tong· Partner· West Coastin

Jeffrey Tong is a Partner at Third Rock Ventures, where he draws on operational experience building and growing early-stage biotechnology companies to focus on drug discovery and development across the firm's portfolio. Before joining Third Rock in 2016, he was Executive Chairman of Delinia, CEO of Nora Therapeutics, and part of the founding management team at Infinity Pharmaceuticals. Earlier in his career he worked at McKinsey & Co and was a founding researcher at the Harvard Bauer Center for Genomics Research. Across his career he has raised capital from equity markets and pharma partnerships and led companies from preclinical through Phase 3 development, integrating science and business strategy.

j•••@thirdrockventures.comreveal

Jigar Raythatha· Partner· East Coastin

Partner at Third Rock Ventures who joined in 2022, previously president and CEO of Constellation Pharmaceuticals until its 2021 acquisition and chief business officer at Jounce Therapeutics through its IPO. He holds an MBA from Columbia and a biochemistry/economics degree from Rutgers, and serves on boards at Flare Therapeutics, Synnovation, and TRIANA Biomedicines.

Kevin Gillis· Partner· East Coastin 𝕏

Kevin Gillis is Partner and Chief Operating Officer at Third Rock Ventures, which he joined in 2008. With more than 25 years of financial leadership and management experience, he leads the firm's non-investment activities, including internal operations, finance, legal, communications, and administrative functions. He also oversees fundraising and manages the firm's limited partner relationships. He is especially interested in the firm's preventive medicine initiatives and their potential to change how cancer and other serious diseases are treated.

k•••@thirdrockventures.comreveal

Reid Huber· Partner· East Coastin 𝕏

Reid Huber is a Partner at Third Rock Ventures, which he joined in 2018, where he works on the formation, development and strategy of the firm's portfolio companies. He brings more than 25 years of operating experience in biotechnology, including as a member of the founding scientific team at Incyte in 2002, where he later served as Executive Vice President and Chief Scientific Officer. Earlier in his career he held roles of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb, and he completed postdoctoral training at the National Institutes of Health. His investing interests center on companies combining disease genetics, data science and translational medicine to create new medicines.

r•••@thirdrockventures.comreveal

Robert Tepper· Partner· East Coastin

Robert "Bob" Tepper is a physician-scientist and co-founder of Third Rock Ventures, where he has been a partner since 2007. Before venture, he spent more than three decades building and running R&D organizations in biotech, including serving as president of R&D at Millennium Pharmaceuticals, where he helped transform the company from a drug discovery operation into a fully integrated biopharmaceutical company. He also co-founded Cell Genesys/Abgenix. At Third Rock he concentrates on company formation, scientific strategy, and evaluating new company ideas across the firm's portfolio.

b•••@thirdrockventures.comreveal

Alan Ezekowitz· Venture Partner· Princeton, New Jerseyin

A physician scientist who spent over 20 years at Harvard Medical School, heading the Laboratory of Developmental Immunology and MassGeneral Hospital for Children. He later led a franchise at Merck and co-founded Abide Therapeutics, acquired by Lundbeck in 2019.

Courtney Wallace· Venture Partner· East Coastin

Venture Partner at Third Rock Ventures focused on creating, developing, and setting strategy for new biotechnology companies. Previously Chief Business Officer of Beam Therapeutics and held business development roles at Celgene, and serves as an independent board director for Kezar Life Sciences.

Jeb Keiper· Venture Partner· East Coastin

Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.

Jeffrey Finer· Venture Partner· West Coastin

Jeffrey Finer is a physician-scientist who joined Third Rock Ventures as a Venture Partner in 2016, where he focuses on drug discovery and development opportunities across the firm's portfolio. He brings roughly 30 years of research and clinical experience, including 18 years leading drug discovery programs, preclinical development, and translational medicine efforts, and has moved several first-in-class drugs into the clinic. He has developed technology platforms integrating science, instruments, and informatics, holds several patents, and has published widely in peer-reviewed journals. He earned his M.D. and Ph.D. in Biochemistry from Stanford and B.S. degrees in Chemistry and Biology from MIT.

John Keilty· Venture Partner· East Coastin 𝕏

John Keilty is a venture partner at Third Rock Ventures, where he works with the platform team to develop and refine technology roadmaps across the portfolio, focusing on identifying and integrating drug discovery and development technology platforms. Before joining Third Rock in 2014, he spent nearly 13 years at Infinity Pharmaceuticals, ultimately serving as vice president of information technology and informatics, where he oversaw information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. He holds a biology degree from Clark University and a master's in bioinformatics from Brandeis University. He is based on the East Coast.

Mary Lynne Hedley· Venture Partner· East Coast

A scientist by training who focuses on new company formation and therapeutic discovery and development, keeping patients central to her work. She co-founded and co-led TESARO before its acquisition by GSK and has held executive leadership roles across biotech and pharma, developing medicines primarily for cancer patients. She holds a B.S. from Purdue, a Ph.D. in Immunology from UT Southwestern, and completed post-doctoral fellowships at Harvard; she joined the firm in 2023.

Richard Ransohoff· Venture Partner· East Coastin 𝕏

Richard Ransohoff is a neurologist who serves as a Venture Partner at Third Rock Ventures, where he focuses on neuroinflammation research and development opportunities. He joined the firm in 2018 from Biogen, and before that spent 30 years at the Cleveland Clinic, where he founded and directed the Neuroinflammation Research Center within the Lerner Research Institute. Trained as a neurologist, he cites a formative moment early in his career — a snowbound day when his clinic was still packed with patients — as a lasting motivation for his work in biotech.

Steve Paul· Venture Partner· East Coastin

Steve Paul is a physician-scientist with over 40 years of experience in neuroscience, molecular neuropharmacology, and CNS drug discovery and development. He spent 18 years at the NIH, including as scientific director of the National Institute of Mental Health, followed by 17 years at Eli Lilly and Company where he rose to Executive Vice President for Science and Technology and President of the Lilly Research Laboratories. He co-founded several CNS-focused biotech companies, including Sage Therapeutics, Voyager Therapeutics (where he was president and CEO), and Karuna Pharmaceuticals (where he served as CEO and chairman). He first joined Third Rock Ventures in 2010 and returned in 2018 as a venture partner, and remains a professor of psychiatry and neurology at Washington University in St. Louis School of Medicine.

Ton Schumacher· Venture Partner· East Coast

Ton Schumacher is a Venture Partner at Third Rock Ventures, where he works on forming new companies in immunology and immuno-oncology. He is a senior member at The Netherlands Cancer Institute and a professor of Immunotechnology at Leiden University. Earlier, he founded AIMM Therapeutics and T cell factory (which was acquired by Kite Pharma) and served as CSO of Kite Pharma EU. His research on T cell recognition in human cancer has earned him honors including the Amsterdam Inventor Award, the Queen Wilhelmina Cancer Research Award, the Meyenburg Cancer Research Award, and the William B. Coley Award.

Vyas Ramanan· Venture Partner· East Coastin 𝕏

Vyas Ramanan is a Venture Partner at Third Rock Ventures, which he joined in 2016, where he helps build new biotech companies at the intersection of biological insight and drug discovery technology to advance medicines for serious diseases. Early in his time at the firm he was involved in the launch of Maze Therapeutics and spent subsequent years helping build its team toward first-in-class medicines. He holds undergraduate and graduate degrees in bioengineering and economics from the University of Pennsylvania, and a Ph.D. from the Harvard-MIT Division of Health Sciences and Technology.

v•••@thirdrockventures.comreveal

Barbara Weber· Venture Partner· Boston, Massachusettsin

Barbara Weber serves as Chairperson of the Board at Tango Therapeutics, a company she helped establish through Third Rock Ventures in 2015 and led as CEO from September 2017 through January 2026. Under her leadership, Tango grew from six employees to over 150 researchers and drug developers focused on cancer genetics, expanding its pipeline to include vopimetostat, a PRMT5 inhibitor entering pivotal development in pancreatic cancer.

Philip Reilly· Venture Partner· Boston, Massachusettsin

Robert Kamen· Venture Partner· Massachusettsin

Adam Tebbe· VP Platform Operations· East Coastin

Adam Tebbe joined Third Rock Ventures in 2023 as Vice President of Platform Operations, focusing on applying technology and data science across the portfolio. He holds a B.S. in Computer Science & Biology from Saint Francis University and an M.S. from the Genome Science and Technology program at the University of Tennessee.

Alison Connors· Chief Financial Officer· East Coastin

CPA overseeing financial strategy and operations for the funds, management company and early-stage portfolio companies, with over 20 years of financial accounting experience in biotech and life sciences. She joined Third Rock Ventures in 2008 and holds a B.S. in Accounting and Finance from Boston College.

Amanda Chan· Senior Manager, Fund Accounting· East Coastin

Amanda Chan handles fund reporting, analysis, operations, and tax matters at Third Rock. She previously worked as a Fund Controller at Dynamo Software and as a Tax Manager at PwC, and is a licensed CPA.

Angelo Severino· Senior Executive Assistant and Office Manager· West Coastin

Angelo manages Third Rock's San Francisco office, handling operations and administrative support. He has prior experience in the tech and hospitality industries.

a•••@thirdrockventures.comreveal

Ava Brunelle· Senior Associate, Fund Accounting· East Coastin

Ava Brunelle joined Third Rock Ventures in 2023 as a Senior Associate in Fund Accounting. She holds a B.S. in Accounting and an M.S. in Taxation from Bentley University.

Cary Pfeffer· Partner· Boston, Massachusettsin

Physician who joined Third Rock in 2007 and led partner development efforts, building relationships with biotech and pharma executives and serving as CBO or CEO of portfolio companies at launch, including work on the Agios-Celgene collaboration. Holds a B.A. from Columbia, an M.D. and MBA from the University of Pennsylvania.

c•••@thirdrockventures.comreveal

Chris Robinson· Chief Talent Officer· East Coastin

Chris leads Third Rock's recruiting team, focused on attracting talent to the firm and its portfolio companies. He joined in 2010, holds a B.S. in Physiology from the University of Massachusetts, and is a former United States Marine.

Corey O'Keeffe· Boston, Massachusetts, United Statesin

Danielle Abdelahad· Vice President, Head of People· East Coastin

Danielle Abdelahad leads Third Rock Ventures' People function, joining in 2025 after leading People & Culture at Jnana Therapeutics through its growth and acquisition. She previously held HR and people operations roles at TRV portfolio companies bluebird bio and Abata Therapeutics, as well as at Wellington Management.

David Moller· Venture Partner· East Coastin

A physician-scientist with over two decades of drug discovery and development experience, David previously held senior R&D leadership roles at Merck and Eli Lilly and served as chief scientific officer at several biotech companies. He began his career as a faculty member at Harvard Medical School.

Erin Moore· Executive Assistant· East Coast

Erin Moore provides administrative support to venture partners at Third Rock and collaborates with the firm's Discovery project teams. She is motivated by the impact of life sciences work on patients.

e•••@thirdrockventures.comreveal

Gabriella Williams· Senior Director, Management Company Controller· East Coastin

Gabby oversees Management Company reporting, analysis, day-to-day operations, and tax matters at Third Rock. She previously served as a Finance Director at Bain Capital and spent several years in tax at EY working with real estate and private equity clients; she is a licensed CPA.

Greg O'Brien· Quincy, Massachusetts, United Statesin

Jason Gehrke· Entrepreneur-in-Residence· West Coastin

Jason Gehrke joined Third Rock Ventures as an Entrepreneur-in-Residence in 2024, focusing on building immunology and genetic medicine companies. He previously held research leadership roles at Beam Therapeutics, including the BEAM-201 program, and holds a PhD in gene editing from Harvard.

Jefte Drijvers· Greater Bostonin

Jesper Gromada· Boston, Massachusetts, United Statesin

Jesper Gromada is a Venture Partner at Third Rock Ventures with experience as a pharmaceutical executive and drug discovery scientist. He has led multidisciplinary teams and directed programs across multiple disease areas, with responsibility for the development of more than 10 drug candidates and marketed drugs. His scientific work includes over 150 publications and 30 patent applications, along with established partnerships across academic and biopharmaceutical institutions.

Julie Yang· Vice President, Project and Portfolio Analytics· East Coastin

Julie Yang, PhD, is VP of Project and Portfolio Analytics at Third Rock Ventures, joining in 2026 after investment roles at TCG Crossover, Leaps by Bayer, and Bain Capital Life Sciences, plus earlier work as a scientist at Dicerna Pharmaceuticals. She holds a PhD in molecular biology from Weill Cornell and an MBA from INSEAD.

Kevin Munnelly· SVP, Platform Technologies· East Coastin

Kevin leads technology R&D at Third Rock, developing platforms and services for wet lab and data sciences across drug discovery and development. Before joining in 2021, he spent a decade building and leading life science technology startups, including as EIR at Biological Engineering Ventures and as President and CEO of Gen9 (acquired by Ginkgo Bioworks), with earlier roles at Life Technologies, Millennium Pharmaceuticals and Applied Biosystems.

Laura Vitale· Senior Executive Assistant· East Coastin

Laura Vitale is a Senior Executive Assistant at Third Rock Ventures who provides administrative support to the human resources and recruiting teams. She holds a B.S. in Communications from Salem State University and has been with the firm since 2010.

l•••@thirdrockventures.comreveal

Lee Venezia· Senior Executive Assistant· East Coast

Lee provides administrative support to Third Rock Ventures' operations team, assisting with planning and strategy initiatives. She has spent the past decade working in biotech.

l•••@thirdrockventures.comreveal

Lisa Pepdjonovic· Human Resources & Recruiting Associate· East Coastin

Lisa supports Third Rock's recruiting team with executive search and internal recruiting across all levels. She joined in 2021 and holds a B.S. in Marketing Management from the University of Massachusetts, Boston.

l•••@thirdrockventures.comreveal

Lisa Purcell· Entrepreneur-in-Residence· Westchester County, New Yorkin

Immunology and infectious disease drug developer who joined Third Rock Ventures as an Entrepreneur-in-Residence in 2024. She previously served as SVP and Head of Research and Translational Medicine at Vir Biotechnology and led development programs at Regeneron, and co-chaired the NIH's ACTIV partnership during COVID-19.

Nasra Mohamed· Human Resources Specialist· East Coastin

Nasra supports Third Rock's HR functions, including benefits administration, employee relations, and policy updates, and assists with HR and recruiting events. She previously worked as an administrator for an intensive care unit and holds a B.S. in Psychology from Suffolk University.

Olie Luchitsky· Receptionist & Senior Administrative Assistant· West Coastin

Olie Luchitsky joined Third Rock Ventures in 2023, providing administrative support to associates, principals, and projects. She previously worked at healthcare technology company 100Plus as one of its earliest employees and brings over a decade of operational experience.

o•••@thirdrockventures.comreveal

Paul Melone· Senior Director, IT· East Coastin

Paul Melone joined Third Rock Ventures in 2023 as Senior Director of IT after 22 years in various roles at Infinity Pharmaceuticals. He holds a B.A. from St. Anselm College and a B.S. in Civil Engineering from Catholic University.

Rebecca Mancusi· Boston, Massachusetts, United Statesin

Richard Chesworth· Boston, Massachusetts, United Statesin

Sara DeAmicis· Boston, Massachusetts, United Statesin

Scott Frechette· Boston, Massachusetts, United Statesin

Stacey Hero· Boston, Massachusetts, United Statesin

Tracy Williams· Senior Executive Assistant· East Coastin

Tracy Williams supports the firm's operations by providing administrative assistance to partners, venture partners, and staff. She joined Third Rock in 2016 and studied at Salem State University.

t•••@thirdrockventures.comreveal

Walter Kowtoniuk· Venture Partner· East Coastin

Walter Kowtoniuk, a Ph.D. in Chemical Biology from Harvard, focuses on genetics and genomics to inform disease biology and drug discovery. He works at the intersection of science, business, and strategy to launch patient-centric biotech companies.

Zoe Angell· Senior Executive Assistant· East Coastin

Zoe Angell is a Senior Executive Assistant at Third Rock Ventures who joined in 2008 and manages operations and administrative functions for partners and venture partners. She holds a B.F.A. from the Rhode Island School of Design.

z•••@thirdrockventures.comreveal

Hugo Hilton· Senior Associate· San Francisco Bay Areain 𝕏

Hugo Hilton is a co-founder and VP of Strategy & Operations at Stealth Mode Biotech, holding a DVM and PhD. His background spans strategy, financing, drug development, and business development in venture-backed biotechnology companies.

h•••@thirdrockventures.comreveal

Andrew Warren· Senior Associate· Berkeley, Californiain

Beryl Cummings· Senior Associate· San Francisco, California𝕏

George Xu· Senior Associate· San Francisco, Californiain

Founder mafia

The Third Rock Ventures mafia →

16 people who came through Third Rock Ventures went on to found or lead other companies.

Reid HuberPartnerFounded MOMA Therapeutics +2 Christoph LengauerPartnerFounded Celsius Therapeutics +2 Steve PaulVenture PartnerFounded Voyager Therapeutics, Inc. +1 Alexis BorisyPartnerFounded Foundation Medicine +1 Philip ReillyVenture PartnerFounded Luna Genetics +1 Abbie CelnikerPartnerFounded Eleven Biotherapeutics Jeffrey FinerVenture PartnerFounded Septerna Jeffrey TongPartnerFounded Nora Therapeutics Carlos LoyaConsultantFounded Aldebaran Therapeutics Lou TartagliaPartnerFounded Solstice Biologics Alexandra (Sandra) GlucksmannEntrepreneur In ResidenceFounded Sensorium Therapeutics Jakob LovenSenior Investment ProffesionalFounded Relay Therapeutics

+ 4 more

What they invest in

from 55 of 60 portfolio companies

Biotech ×49Healthtech ×15Medical Devices ×8AI & Machine Learning ×5Deep Tech ×3Crypto & Web3 ×2Enterprise Software ×2Data & Infrastructure ×1

HQs:United States×49Japan×1Kenya×1Norway×1

Investments · 60 tracked

founders shown can be your intro path

By year:2026 · 4 2025 · 7 2024 · 3 2023 · 2 2021 · 2 2020 · 5 2019 · 3 2018 · 4 2017 · 1 2016 · 4 2015 · 11 2014 · 349 dated

CytomX TherapeuticsNASDAQ: CTMXDec 2014SEC filingmedium confidence

Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.

BiotechSouth San Francisco, US

Sean McCarthy(Executive Officer, Director)

BoardTim Shannon(Director)inElaine V. Jones(Director)Frederick W. Gluck(Director)Hoyoung Huh(Director)

Board seatNeil Exter· per SEC Form D · $30M raise · filed Jan 2015

Co-investorsLongitude Capital Canaan Partners

Fulcrum TherapeuticsNASDAQ: FULCJul 2016SEC filinghigh confidence

BiotechCambridge, US

Robert Gould(Executive Officer, Director)

BoardAlan Ezekowitz(Director)inJames Geraghty(Director)James Collins(Director)

Board seatMark Levin· per SEC Form D · $55M raise · filed Jul 2017

Co-investorsForesite Capital

KALA BIOkalarx.comNASDAQ: KALAAug 2015SEC filingmedium confidence

BiotechArlington, US

Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)

Board seatRobert Tepper· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude Capital SR One Capital Management Ysios Capital Atlas Venture Lux Capital

Pliant Therapeuticspliantrx.com in 𝕏NASDAQ: PLRXJul 2018SEC filinghigh confidence

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.

BiotechSouth San Francisco, US

Bernard Coulie(Executive Officer, Director)Johannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)

BoardKevin Raidy(Director)

Board seatCharles HomcyNeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018

Co-investorsMenlo Ventures Agent Capital

Revolution MedicinesNASDAQ: RVMDMar 2018SEC filinghigh confidence

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Board seatNeil ExterBarbara Weber· per SEC Form D · $100.3M raise · filed Nov 2019

Co-investorsBain Capital Life Sciences Foresite Capital Nextech Invest

Tango Therapeuticstangotx.comNASDAQ: TNGXAug 2023

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Board seatAlexis BorisyReid Huber· per SEC Form D

Co-investorsForesite Capital Nextech Invest NSG Ventures

Voyager Therapeutics, Inc.NASDAQ: VYGRApr 2015SEC filingmedium confidence

NASDAQ-listed (VYGR) biotech in Lexington, MA developing AAV gene therapies and antibodies for neurological diseases.

BiotechLexington, US

Robin Swartz(Executive Officer)Alfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)Steven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)

Board seatMark Levin· per SEC Form D · filed Apr 2015

Co-investorsARCH Venture Partners

Agios Pharmaceuticalsagios.com in 𝕏NASDAQ: AGIO

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Co-investorsARCH Venture Partners

Azalea Therapeuticsazaleatx.com inNov 2025✓ verified

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in

Co-investorsRA Capital Sozo Ventures Yosemite

Merida Biosciencesmeridabio.com in✓ verified

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Michael Naill(Senior Vice President, Process and Product Development)Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)

Co-investorsBain Capital Life Sciences Biotechnology Value Fund GV (Google Ventures)

Syremis Therapeuticssyremis.com inDec 2025 · $165M✓ verified

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsBain Capital Life Sciences GV (Google Ventures)

Vibe Biovibebio.com in 𝕏✓ verified

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps.

AI & Machine LearningBiotechEnterprise Software

Alok Tayi(CEO & Founder)

Co-investors6th Man Ventures AlleyCorp Undeterred Capital Alley Robotics Ventures

Afferent PharmaceuticalsJul 2015SEC filingmedium confidence

BiotechSan Mateo, US

Anthony Ford(Executive Officer)Michael Kitt(Executive Officer)Kathleen Sereda Glaub(Executive Officer, Director)

BoardArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatKevin Starr· per SEC Form D · $55M raise · filed Jul 2015

Co-investorsPappas Capital Domain Associates

Allena PharmaceuticalsNov 2015SEC filingmedium confidence

BiotechNewton, US

Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)

BoardAxel Bolte(Director)James Topper(Director)Stephen Kraus(Director)

Board seatRobert Tepper· per SEC Form D · $53M raise · filed Dec 2015

Co-investorsPontifax Venture Capital Frazier Life Sciences

Arbor Biotechnologiesarbor.bio in 𝕏Oct 2021SEC filingmedium confidence

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in

Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021

Co-investorsARCH Venture Partners Illumina Ventures Ono Venture Investment, Inc.TCG Crossover

Asher Biotherapeutics, Inc.Apr 2024SEC filingmedium confidence

BiotechSouth San Francisco, US

Ivana Djuretic(Executive Officer, Director, Promoter)Yik Andy Yeung(Executive Officer, Director, Promoter)

Board seatJeffrey TongReid Huber· per SEC Form D · $55M raise · filed Apr 2024

AtterocorDec 2017SEC filingmedium confidence

BiotechAnn Arbor, US

Julia C. Owens(Executive Officer, Director)

BoardCarol Gallagher(Director)James Topper(Director)William Harrington(Director)Randall Whitcomb(Director)

Board seatMary Lynne Hedley· per SEC Form D · $59.1M raise · filed Dec 2017

Co-investorsFrazier Life Sciences

Cardurion Pharmaceuticals, Inc.Nov 2019SEC filingmedium confidence

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)

Board seatJeb Keiper· per SEC Form D · $10M raise · filed Nov 2019

Co-investorsBain Capital Life Sciences Bain Capital NEA Secondary Polaris Partners

Cedilla Therapeutics, Inc.Sep 2020SEC filinghigh confidence

BiotechCambridge, US

Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Chris Bowden(Director)Jake Simson(Director)Rosana Kapeller(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · $82.6M raise · filed Oct 2021

Co-investorsCasdin Capital

Constellation Pharmaconstellationpharma.com in 𝕏Dec 2015acquired by NovartisSEC filingmedium confidence

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Board seatRobert Tepper· per SEC Form D · $55.8M raise · filed Dec 2015

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Venrock The Column Group

Corvia MedicalJun 2025SEC filingmedium confidence

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)

BoardPaul LaViolette(Director)inGerald Brunk(Director)inIrit Yaniv(Director)

Board seatKevin GillisMark Levin· per SEC Form D · $11.1M raise · filed Jun 2025

Co-investorsAccelmed Partners Lumira Ventures SV Health Investors

Decibel TherapeuticsOct 2015acquired by Regeneron

Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.

Cambridge, US

Board seatNeil ExterCraig MuirKevin Starr· per SEC Form D

Co-investorsage1 Samsara BioCapital

Element Sciencemyjewel.com inAug 2016

Jewel is a wearable patch cardioverter defibrillator designed to provide continuous protection from sudden cardiac arrest, using machine learning to minimize false alarms while requiring no daily maintenance for up to a week.

AI & Machine LearningHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)William Kucheman(Director)

BoardRussell Hirsch(Director)Krishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seatNeil Exter· per SEC Form D

Co-investorsDeerfield Management Company GV (Google Ventures)

Eleven BiotherapeuticsMar 2018SEC filingmedium confidence

BiotechCambridge, US

Stephen Hurly(Executive Officer, Director)John McCabe(Executive Officer)Arthur P. DeCillis(Executive Officer)David A. Berry(Executive Officer, Director)Gregory D. Perry(Executive Officer)Eric S. Furfine(Executive Officer)

Board seatAbbie Celniker· per SEC Form D · $996K raise · filed Apr 2018

Faze MedicinesDec 2020

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

BoardCary Pfeffer(Executive Officer, Director)in

PartnerCary Pfeffer· quoted

Board seatCharles HomcyRobert Tepper· per SEC Form D

Global Blood TherapeuticsDec 2014

South San Francisco, US

John Schembri(Executive Officer)Ted W. Love(Executive Officer, Director)

BoardCharles Homcy, M.D.(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsRA Capital

Goldfinch BioPharmaJun 2020SEC filinghigh confidence

HealthtechCambridge, US

PETER THOMSON(Executive Officer)

BoardLOUIS BRENNER(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · filed Jul 2020

Hookipa PharmaFeb 2019SEC filingmedium confidence

BiotechNew York, US

Joern Aldag(Executive Officer, Director)Reinhard Kandera(Executive Officer, Director)Paul-Henri Lambert(Director)Michael Kelly(Director)Julie O'Neill(Director)Sander van Deventer(Director)

Board seatChristoph Lengauer· per SEC Form D · filed Feb 2019

Co-investorsSofinnova Partners

ImaginabMar 2016SEC filingmedium confidence

BiotechInglewood, US

Anna M. Wu(Executive Officer, Director)Jeffrey D. Quan(Executive Officer)Benjamin Chen(Executive Officer)Valerie Calenda(Director)Anna W. Work(Director)Jennifer Keppler(President and Chief Operating Officer)

Board seatAbbie Celniker· per SEC Form D · $9.5M raise · filed Apr 2016

Jounce Therapeuticsjouncetx.comApr 2015

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)Richard Murray(Executive Officer, Director)

Board seatRobert KamenCary PfefferRobert Tepper· per SEC Form D

Co-investorsNextech Invest

Kamal Therapeuticskamaltherapeutics.comNov 2025SEC filingmedium confidence

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.

BiotechHealthtechHingham, US

Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)

Board seatPhilip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025

LyceraJun 2015DefunctSEC filingmedium confidence

Ann Arbor-founded biopharmaceutical company developing small molecule immunomodulators for autoimmune diseases and cancer.

BiotechAnn Arbor, US

Paul Sekhri(Executive Officer)Gary Glick(Executive Officer, Director)Steve Gillis(Director)Kathleen M. Metters(Executive Officer, Director)

BoardMichael Hayden(Director)

Board seatRobert Kamen· per SEC Form D · filed Jun 2015

Co-investorsARCH Venture Partners Canaan Partners

Manifold BiotechnologiesNov 2024SEC filingmedium confidence

BiotechBoston, US

Gleb Kuznetsov(Executive Officer, Director)Pierce Ogden(Executive Officer, Director)

BoardJory Bell(Director)Jeff Huber(Director)Steven Holtzman(Director)

Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024

MyokardiaApr 2015SEC filinghigh confidence

BiotechSouth San Francisco, US

Tassos Anastasios Gianakakos(Executive Officer, Director)

BoardMark Perry(Director)Katherine Bowdish(Director)

Board seatCharles HomcyKevin Starr· per SEC Form D · $46M raise · filed Apr 2015

Co-investorsForesite Capital Khosla Ventures

Neon Therapeuticsneontherapeutics.comDec 2016

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)Eric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Board seatRobert KamenRobert Tepper· per SEC Form D

Co-investorsNextech Invest Sofinnova Ventures Clal Biotechnology Industries

NinePoint MedicalNov 2015SEC filingmedium confidence

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)Eric Swanson(Director)Judith M. Huber(Executive Officer)Charles Carignan(Executive Officer, Director)

BoardRussell Hirsch(Director)

Board seatMark Levin· per SEC Form D · $40.7M raise · filed Nov 2015

Nominalfaction.vc 𝕏Jun 2021SEC filinghigh confidence

Faction is a venture capital firm that invests in cryptocurrency and blockchain projects at the seed and series A stages, focusing on entrepreneurs building fundamental utility across the technology stack.

BiotechCrypto & Web3New York, US

Oren Harnevo(Executive Officer, Director)Ronald Bianchini, Jr.(Executive Officer, Director)Christina Calvaneso(Executive Officer)Brian Pozesky(Executive Officer)Jeff Fagel(Executive Officer)SAMANTHA SINGER(Executive Officer, Director)

Board seatDavid KaufmanAbbie Celniker· per SEC Form D · filed Dec 2023

Co-investorsAccel Adaverse Aleph Axeleo Capital Bluebird Ventures Bright Pixel Capital +36 more

PanOpticapanopticapharma.comApr 2014SEC filingmedium confidence

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)Kevin Starr(Director)Lutz Giebel(Director)Colin Goddard(Director)

BoardDavid Guyer(Director)

Board seatAbbie Celniker· per SEC Form D · $47.3M raise · filed Apr 2019

Co-investorsAstellas Venture Management LLC Agent Capital

Platelet BioGenesisplateletbiogenesis.comJun 2019SEC filingmedium confidence

BiotechChestnut Hill, US

Joseph Italiano(Director)Jonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)

Board seatPhilip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019

Co-investorsBoston Harbor Angels Qiming Healthcare

Rheos MedicinesMar 2018SEC filinghigh confidence

BiotechCambridge, US

Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)

Board seatAbbie CelnikerCary Pfeffer· per SEC Form D · filed Nov 2018

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Aug 2015SEC filingmedium confidence

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inTodd Foley(Director)

Board seatNeil Exter· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments OrbiMed

Sage TherapeuticsDec 2020SEC filingmedium confidence

BiotechHealthtechCambridge, US

Barry Greene(Executive Officer, Director)Kimi Iguchi(Executive Officer)Michael Cloonan(Executive Officer)Anne Marie Cook(Executive Officer)Stephen J. Kanes(Executive Officer)Jeffrey M. Jonas(Executive Officer, Director)

Board seatKevin Starr· per SEC Form D · $650M raise · filed Jan 2021

Septernasepterna.comJun 2023SEC filingmedium confidence

Septerna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform.

BiotechDeep TechSouth San Francisco, US

Board seatJeffrey Tong· per SEC Form D · $150M raise · filed Jul 2023

Co-investorsCatalio Capital Management, LP RA Capital Samsara BioCapital Vertex Ventures HC

Strand TherapeuticsMay 2025SEC filingmedium confidence

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

BiotechBoston, US

Jeb Keiper(Director)Ala Alenazi(Director)Pegah Ebrahimi(Director)Tasuku Kitada(Executive Officer, Director, Promoter)Samta Kundu(Executive Officer)Jory Bell(Director)

Board seatJeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026

Co-investorsJIC Venture Growth Investments Kinnevik Playground Global Amgen Ventures ANRI FPV +2 more

Terremotobioterremotobio.comApr 2026 · $108M

Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)

BoardMichael Goller(Director)Peter Thompson(Director)

Board seatReid Huber· per SEC Form D

Co-investorsEcoR1 Capital OrbiMed RA Capital Novo Holdings Osage University Partners

Triana Biomedicines, Inc.Dec 2025SEC filingmedium confidence

Lexington, US

Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsAtlas Venture OpenSky Ventures

Agios

Developer of Aqvesme (mitapivat), an FDA-approved medicine for anemia in thalassemia.

Alcrestaalcresta.com in

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

Daniel Orlando(Chief Executive Officer)Tasos Konidaris(Executive Officer)Martin Paz(Executive Officer)Robert Gallotto(Executive Officer)Daniel Tasse(Executive Officer, Director)William Scheinler(Executive Officer)

Co-investorsHealthQuest Capital Bessemer Venture Partners Frazier Life Sciences

Asher Bioasherbio.com in 𝕏

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture Partners GoAhead Ventures Mission Bay Capital Mission Biocapital RA Capital Y Combinator

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite Capital OrbiMed Samsara BioCapital TCG Crossover venBio Partners Vida Ventures

CARGO Therapeuticscargo-tx.com

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNextech Invest Red Tree Venture Samsara BioCapital Ally Bridge Group Janus Henderson Investors Perceptive Xontogeny Venture

Clasp Therapeuticsclasptx.com in

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LP Cure Ventures Vivo Capital Catalio Capital Management Novo Holdings

Flareflare.co.ke 𝕏Jun 2026 · $85M

Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.

Enterprise SoftwareGovTechSaaSNairobi, KE

Co-investors4Di Capital Inovia Capital Agent Capital Base10 Partners Casdin Capital Invus +3 more

Flareflare.xyz in 𝕏Jun 2026 · $85M

Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.

Crypto & Web3Data & Infrastructure

Co-investorsDigital Currency Group Agent Capital Base10 Partners Casdin Capital Inovia Capital Invus +3 more

Flareflare.runJul 2026 · $85M

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKA CARTA VENTURES, Inc.Spiral Ventures Agent Capital Base10 Partners Casdin Capital +5 more

Healthcare North America Growth Stageartbio.com in 𝕏Jul 2025

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)

Co-investorsB Capital Group B4 Capital F-Prime Capital Alexandria B Capital Qatar Investment Authority+1 more

Insitroinsitro.com in 𝕏Mar 2020

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Foresite Capital GV (Google Ventures)HOF Capital SoftBank Vision Fund +5 more

MOMA Therapeuticsmomatx.com in 𝕏

Moma Therapeutics is a biotechnology company developing precision medicines by targeting molecular machines that drive human disease.

Biotech

Co-investorsNextech Invest Goldman Sachs

Synnovation Therapeuticssynnovationtx.com in

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)Wenqing Yao(Executive Officer, Director)Ting Feng(Director)

BoardReid Huber(Director)in

Co-investorsNextech Invest The Innovation Space

Taris Bioacquired by Johnson & Johnson

Originator of Inlexzo (gemcitabine intravesical system), an FDA-approved treatment for certain bladder cancers; acquired by Johnson & Johnson in 2019.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 11

IPOs and acquisitions across the tracked portfolio

CytomX TherapeuticsNASDAQ: CTMXFulcrum TherapeuticsNASDAQ: FULCKALA BIONASDAQ: KALAPliant TherapeuticsNASDAQ: PLRXRevolution MedicinesNASDAQ: RVMDTango TherapeuticsNASDAQ: TNGXVoyager Therapeutics, Inc.NASDAQ: VYGRAgios PharmaceuticalsNASDAQ: AGIOConstellation Pharmaacq. by NovartisDecibel Therapeuticsacq. by RegeneronTaris Bioacq. by Johnson & Johnson

Portfolio news

latest coverage across their companies

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com

Rhythm Pharmaceuticals · investing.com · Aug 17, 2026

What's Going On With Fulcrum Therapeutics Stock Monday? - Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga

Fulcrum Therapeutics · benzinga.com · Aug 17, 2026

JPMorgan Chase & Co. Cuts CytomX Therapeutics (NASDAQ:CTMX) Price Target to $11.00 - Ticker Report

CytomX Therapeutics · tickerreport.com · Aug 16, 2026

KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks.com

KALA BIO · tipranks.com · Aug 14, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Terremotobio · fiercebiotech.com · Aug 12, 2026

Scammers stole millions of XRP tokens from dozens of investors via a fake Flare Network site

Flare · coindesk.com · Jul 30, 2026

Mizuho raises Tango Therapeutics stock price target on combo data By Investing.com

Tango Therapeutics · investing.com · Jul 17, 2026

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

Agios Pharmaceuticals · sahmcapital.com · Jul 15, 2026

Public market activity · per SEC filings

what is this? ⓘ

Files 13F institutional holdings reports · latest Nov 2015

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Third Rock Ventures made?: Third Rock Ventures has 12 tracked investments, 3 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
What stage does Third Rock Ventures invest at?: Third Rock Ventures invests at the Seed, Series A, Series B, Series C stages.
What is Third Rock Ventures's typical check size?: Third Rock Ventures typically writes checks of $100K – $5M.
What sectors does Third Rock Ventures focus on?: Third Rock Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Third Rock Ventures located?: Third Rock Ventures is headquartered in Boston, US.
Does Third Rock Ventures lead rounds?: Third Rock Ventures typically participates in rounds rather than leading them.
Who does Third Rock Ventures co-invest with?: Third Rock Ventures most often shares deals with Nextech Invest, Foresite Capital, Samsara BioCapital, among 13 tracked co-investors.

Media · Podcasts & interviews

from their channel

Connected By Our Mission

Third Rock Ventures

Third Rock: First Decade Video

Third Rock Ventures

Images

Co-investors · 36

Nextech Invest

Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.

Both backed · 8

Revolution Medicines Tango Therapeutics CARGO Therapeutics Flare Jounce Therapeutics MOMA Therapeutics Neon Therapeutics Synnovation Therapeutics

$648K – $3.2M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.

Both backed · 5

Agios Pharmaceuticals Voyager Therapeutics, Inc.Arbor Biotechnologies Insitro Lycera

$50K – $250M

RA Capital

RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.

Both backed · 5

Asher Bio Azalea Therapeutics Global Blood Therapeutics Septerna Terremotobio

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 4

Element Science Insitro Merida Biosciences Syremis Therapeutics

$250K – $50M

Samsara BioCapital

Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.

Both backed · 4

Candid Therapeutics CARGO Therapeutics SepternaDecibel Therapeutics

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 3

Candid Therapeutics Rhythm Pharmaceuticals Terremotobio

$1M – $75M

Casdin Capital

Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.

Both backed · 3

Cedilla Therapeutics, Inc.Flare Insitro

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 2

CytomX Therapeutics Lycera

$500K – $20M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 2

KALA BIOTriana Biomedicines, Inc.

$500K – $1M

Sofinnova Ventures

Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.

Both backed · 2

Neon TherapeuticsHealthcare North America Growth Stage

$100K – $15M

Catalio Capital Management, LP

Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.

Both backed · 2

Clasp Therapeutics Septerna

General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

Both backed · 1

Nominal

$30M

▶24 more co-investors

Bessemer Venture Partners B Capital Group F-Prime Capital Venrock SR One Capital Management venBio Partners The Column Group Pfizer Venture Investments SV Health Investors Vivo Capital Ysios Capital Catalio Capital Management Astellas Venture Management LLC Bain Capital Ventures Unknown Ventures Foundry Flare Capital Partners S32 Forbion Johnson & Johnson Innovation – JJDC Flagship Pioneering Frazier Healthcare Partners Andera Partners Activate Venture Partners

Firms observed investing alongside Third Rock Ventures, from public investor directories. Shared companies are the overlap with Third Rock Ventures's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

$250K – $50M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Healthtech Investors & VC Firms Series C Investors & VC Firms Healthtech Seed Investors & VC Firms